Robin Alexander Emsley

Robin Alexander Emsley's AcademicInfluence.com Rankings

Biology

#12730

World Rank

#16226

Historical Rank

biology Degrees

Download Badge

Biology

Robin Alexander Emsley's Degrees

PhD Psychiatry University of Manchester
Masters Medicine University of Manchester

Why Is Robin Alexander Emsley Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Robin Alexander Emsley's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis (2003) (355)
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. (2005) (350)
Psychometric properties of the Multidimensional Scale of Perceived Social Support in youth. (2008) (336)
The nature of relapse in schizophrenia (2013) (333)
Placebo-controlled trial of agomelatine in the treatment of major depressive disorder (2006) (317)
Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. (2002) (278)
A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. (2003) (236)
Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study (2007) (231)
Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. (1999) (195)
Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates (2007) (190)
Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. (2009) (189)
A comparison of the effects of quetiapine (‘Seroquel’) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment (2000) (174)
The concepts of remission and recovery in schizophrenia (2011) (166)
TREATMENTS (2012) (160)
Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. (1997) (159)
Ethnicity and treatment response in schizophrenia: a comparison of 3 ethnic groups. (2002) (150)
Social isolation rearing induces mitochondrial, immunological, neurochemical and behavioural deficits in rats, and is reversed by clozapine or N-acetyl cysteine (2013) (146)
Time course for antipsychotic treatment response in first-episode schizophrenia. (2006) (139)
Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder. (1999) (132)
Linking Posttraumatic Stress Disorder and Psychosis: A Look at Epidemiology, Phenomenology, and Treatment (2003) (120)
Mental health literacy: focus on developing countries. (2008) (118)
Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection (2008) (112)
Comparison of response to a selective serotonin reuptake inhibitor in children, adolescents, and adults with posttraumatic stress disorder. (2002) (108)
Predictors of long-term outcome in schizophrenia (2008) (104)
Remission in first-episode psychosis: predictor variables and symptom improvement patterns. (2006) (103)
The evidence for illness progression after relapse in schizophrenia (2013) (102)
Long-Acting Injectable Risperidone in the Treatment of Subjects With Recent-Onset Psychosis: A Preliminary Study (2008) (100)
Isolation rearing-induced deficits in sensorimotor gating and social interaction in rats are related to cortico-striatal oxidative stress, and reversed by sub-chronic clozapine administration (2011) (98)
HIV infection and the fronto–striatal system: a systematic review and meta-analysis of fMRI studies (2014) (95)
The effects of eicosapentaenoic acid in tardive dyskinesia: A randomized, placebo-controlled trial (2006) (93)
A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. (2004) (91)
Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. (2008) (82)
Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies (2008) (81)
Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia (2012) (78)
A systematic review of genetic variants associated with metabolic syndrome in patients with schizophrenia (2016) (77)
Duration of untreated psychosis and outcome in first‐episode psychosis. Perspective from a developing country (2005) (74)
Neurological abnormalities in first-episode schizophrenia: temporal stability and clinical and outcome correlates (2005) (73)
Long-Acting Formulations of Atypical Antipsychotics (2007) (69)
Evidence-based pharmacotherapy of schizophrenia. (2004) (68)
Causal attributions, pathway to care and clinical features of first-episode psychosis: A South African perspective (2011) (68)
Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder (2002) (68)
Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. (2004) (68)
Alcohol-induced psychotic disorder: a review (2014) (67)
Comparison of Treatment Response in Second-Episode Versus First-Episode Schizophrenia (2013) (65)
Clinical Potential of Omega-3 Fatty Acids in the Treatment of Schizophrenia (2003) (65)
Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. (2003) (65)
A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. (2009) (62)
Deficits in facial affect recognition in unaffected siblings of Xhosa schizophrenia patients: Evidence for a neurocognitive endophenotype (2008) (61)
Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study. (2012) (61)
Focus on psychiatry in South Africa. (2001) (61)
Association between a catechol-o-methyltransferase polymorphism and obsessive-compulsive disorder in the Afrikaner population. (2001) (60)
A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis. (2004) (60)
Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations (2020) (59)
The genetic architecture of schizophrenia, bipolar disorder, obsessive-compulsive disorder and autism spectrum disorder (2018) (58)
Attitudes towards and beliefs about schizophrenia in Xhosa families with affected probands. (2002) (58)
Differential Effect of Quetiapine on Depressive Symptoms in Patients with Partially Responsive Schizophrenia (2003) (56)
Long‐acting injectable antipsychotics in early psychosis: a literature review (2013) (54)
Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: Results from a randomized, placebo-controlled trial (2008) (54)
Long-Term Assessment of Asenapine vs. Olanzapine in Patients with Schizophrenia or Schizoaffective Disorder. (2011) (53)
DNA methylation and antipsychotic treatment mechanisms in schizophrenia: Progress and future directions (2018) (52)
Obsessive-compulsive disorder and the promoter region polymorphism (5-HTTLPR) in the serotonin transporter gene (SLC6A4): a negative association study in the Afrikaner population. (2000) (51)
Improving Treatment Adherence in Your Patients with Schizophrenia (2013) (51)
The effects of sub-chronic clozapine and haloperidol administration on isolation rearing induced changes in frontal cortical N-methyl-d-aspartate and D1 receptor binding in rats (2010) (50)
The factor structure for positive and negative symptoms in South African Xhosa patients with schizophrenia (2001) (49)
Measuring Anxiety in Patients with Schizophrenia (2007) (49)
Psychiatric manifestations and magnetic resonance imaging in HIV-negative neurosyphilis (1997) (47)
A Culture-Bound Syndrome ‘Amafufunyana’ and a Culture-Specific Event ‘Ukuthwasa’: Differentiated by a Family History of Schizophrenia and other Psychiatric Disorders (2004) (46)
Depressive symptoms at baseline predict fewer negative symptoms at follow-up in patients with first-episode schizophrenia (2002) (46)
Serum concentrations of some metals and steroids in patients with chronic fatigue syndrome with reference to neurological and cognitive abnormalities (2001) (46)
A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia (2014) (46)
Determining the optimal dose of haloperidol in first-episode psychosis (2001) (45)
Childhood adversity and cognitive function in schizophrenia spectrum disorders and healthy controls: evidence for an association between neglect and social cognition (2017) (44)
Crisis discharges and readmission risk in acute psychiatric male inpatients (2008) (43)
Next-generation sequencing of pharmacogenes: a critical analysis focusing on schizophrenia treatment (2013) (40)
Anxiety disorders and schizophrenia (2004) (40)
Emotional face processing deficit in schizophrenia: A replication study in a South African Xhosa population (2006) (39)
Partial response to antipsychotic treatment: the patient with enduring symptoms. (1999) (38)
Psychiatric manifestations of neurosyphilis. (1992) (38)
Mass Murders: Implications for Mental Health Professionals (2008) (38)
Long-term assessment of Asenapine vs. Olanzapine in patients with schizophrenia or schizoaffective disorder. (2010) (38)
Violence in male patients with schizophrenia: risk markers in a South African population. (2004) (37)
A new model for the pathophysiology of Alzheimer's disease. Aluminium toxicity is exacerbated by hydrogen peroxide and attenuated by an amyloid protein fragment and melatonin. (1997) (37)
Open trial of citalopram in adults with post-traumatic stress disorder. (2000) (37)
The relationships between depression and remission in first-episode psychosis. (2006) (35)
Drugs in development for the treatment of schizophrenia (2009) (35)
A double-blind placebo-controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa. (1999) (34)
Pathways to inpatient mental health care among people with schizophrenia spectrum disorders in South Africa. (2010) (33)
Brain volume changes over the first year of treatment in schizophrenia: relationships to antipsychotic treatment (2017) (33)
Zinc and platelet membrane microviscosity in Alzheimer's disease. The in vivo effect of zinc on platelet membranes and cognition. (1997) (33)
Stereotypies: Prevalence and Association with Compulsive and Impulsive Symptoms in College Students (1999) (32)
Social isolation rearing in rats alters plasma tryptophan metabolism and is reversed by sub-chronic clozapine treatment (2012) (32)
Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia (2004) (32)
Rate and predictors of non‐response to first‐line antipsychotic treatment in first‐episode schizophrenia (2015) (31)
Water excretion and plasma vasopressin in psychotic disorders. (1989) (30)
A treatment algorithm (2001) (30)
The new and evolving pharmacotherapy of schizophrenia. (2003) (29)
Early intervention in schizophrenia in developing countries: Focus on duration of untreated psychosis and remission as a treatment goal (2012) (29)
Changes in Body Mass and Metabolic Profiles in Patients with First-Episode Schizophrenia Treated for 12 Months with A First-Generation Antipsychotic (2015) (28)
Posttraumatic Stress Disorder and Occupational Disability in South African Security Force Members (2003) (28)
Long-Term Efficacy and Safety of Asenapine or Olanzapine in Patients with Schizophrenia or Schizoaffective Disorder: An Extension Study (2012) (28)
Cognitive performance during the first year of treatment in first-episode schizophrenia: a case–control study (2015) (28)
Positive and negative symptoms in affected sib pairs with schizophrenia: Implications for genetic studies in an African Xhosa sample (2005) (27)
Family therapy for schizophrenia: cultural challenges and implementation barriers in the South African context. (2011) (27)
Treatment of schizophrenia in low-income countries. (1999) (26)
Effects of quetiapine and haloperidol on body mass index and glycaemic control: a long-term, randomized, controlled trial. (2005) (26)
Towards a treatment model for family therapy for schizophrenia in an urban African setting: Results from a qualitative study (2014) (26)
Psychiatrists’ awareness of adherence to antipsychotic medication in patients with schizophrenia: results from a survey conducted across Europe, the Middle East, and Africa (2013) (26)
DSM-III-R classification of psychiatric symptoms in systemic lupus erythematosus. (1996) (25)
Combining depot antipsychotic with an assertive monitoring programme for treating first‐episode schizophrenia in a resource‐constrained setting (2016) (25)
Factors Moderating the Relationship Between Childhood Trauma and Premorbid Adjustment in First-Episode Schizophrenia (2017) (25)
Negative symptoms and HIV/AIDS risk-behavior knowledge in schizophrenia. (2007) (25)
Exposure to trauma and the clinical presentation of first-episode psychosis in South Africa. (2011) (25)
Inappropriate antidiuretic state in long-term psychiatric inpatients. (1990) (24)
Early recovery in the first 24 months of treatment in first-episode schizophrenia-spectrum disorders (2020) (24)
Neurological soft signs in first-episode schizophrenia: State- and trait-related relationships to psychopathology, cognition and antipsychotic medication effects (2017) (24)
Recommendations for the optimal care of patients with recent‐onset psychosis in the Asia‐Pacific region (2016) (24)
Posttraumatic Stress Disorder, Overweight, and Obesity: A Systematic Review and Meta-analysis (2016) (23)
Predictors of psychosis breakthrough during 24 months of long-acting antipsychotic maintenance treatment in first episode schizophrenia (2019) (23)
Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia: systematic review and indirect treatment comparison (2017) (23)
Magnetic resonance imaging in alcoholic Korsakoff's syndrome: evidence for an association with alcoholic dementia. (1996) (23)
Alcohol-induced psychotic disorder: brain perfusion and psychopathology—before and after anti-psychotic treatment (2012) (23)
Relapse After Antipsychotic Discontinuation in Schizophrenia as a Withdrawal Phenomenon vs Illness Recurrence: A Post Hoc Analysis of a Randomized Placebo-Controlled Study. (2018) (23)
The new-generation antipsychotics - integrating the neuropathology and pharmacology of schizophrenia (1999) (22)
Whole-genome resequencing in pharmacogenomics: moving away from past disparities to globally representative applications. (2011) (22)
Subjective awareness of tardive dyskinesia and insight in schizophrenia (2011) (22)
Modification of the association between antipsychotic treatment response and childhood adversity by MMP9 gene variants in a first-episode schizophrenia cohort (2018) (22)
Changes in erythrocyte membrane fatty acids during a clinical trial of eicosapentaenoic acid (EPA) supplementation in schizophrenia (2009) (21)
Symptom attribution and frontal cortical thickness in first‐episode schizophrenia (2018) (20)
Anxiety disorders among abstinent alcohol-dependent patients. (1999) (20)
Oral zinc augmentation with vitamins A and D increases plasma zinc concentration: Implications for burden of disease (2006) (20)
Dorsal striatal volumes in never-treated patients with first-episode schizophrenia before and during acute treatment (2015) (19)
Occupational disability on psychiatric grounds in South African school-teachers. (2009) (19)
Obsessive compulsive disorder--prevalence in Xhosa-speaking schizophrenia patients. (2005) (19)
Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review (2018) (19)
Insight and white matter fractional anisotropy in first-episode schizophrenia (2017) (18)
Cannabis use predicts shorter duration of untreated psychosis and lower levels of negative symptoms in first-episode psychosis: a South African study. (2011) (18)
Motor sequencing abnormalities are the trait marking neurological soft signs of schizophrenia (2015) (18)
HIV/AIDS in Africa--a role for the mental health practitioner? (2005) (18)
Is it time to shift to better characterization of patients in trials assessing novel antidepressants? An example of two relapse prevention studies with agomelatine (2013) (17)
Prefrontal cortical thinning in HIV infection is associated with impaired striatal functioning (2016) (17)
Concordance of patient and clinical ratings of symptom severity and change of psychotic illness (2008) (17)
The thyrotropin releasing hormone stimulation test in alcoholism. (1995) (17)
A retrospective chart review of the clinical and psychosocial profile of psychotic adolescents with co-morbid substance use disorders presenting to acute adolescent psychiatric services at Tygerberg Hospital (2012) (17)
Childhood Trauma Associated White Matter Abnormalities in First-Episode Schizophrenia (2018) (17)
Changes in insight over the first 24 months of treatment in schizophrenia spectrum disorders (2019) (16)
Weight gain and metabolic change as predictors of symptom improvement in first-episode schizophrenia spectrum disorder patients treated over 12 months (2019) (16)
Disordered water homeostasis and cognitive impairment in schizophrenia (1993) (16)
P-4-76 Risperidone in the treatment of first-episode patients with schizophreniform disorder: A double-blind multicenter study (1995) (16)
The prevalence of burnout and depression among medical doctors working in the Cape Town metropole community health care clinics and district hospitals of the Provincial Government of the Western Cape: A Cross-Sectional Study (2013) (15)
Screening for syphilis and neurosyphilis in acute psychiatric admissions. (1992) (15)
Violence in the world and in South Africa--what is a doctor to do? (2002) (15)
The identification of novel genetic variants associated with antipsychotic treatment response outcomes in first-episode schizophrenia patients (2016) (15)
Phenomenology of Stereotypic Movement Disorder (1998) (15)
Effects of cannabis use on body mass, fasting glucose and lipids during the first 12 months of treatment in schizophrenia spectrum disorders (2018) (15)
HIV Infection Is Associated with Impaired Striatal Function during Inhibition with Normal Cortical Functioning on Functional MRI (2015) (15)
Patterns of variation influencing antipsychotic treatment outcomes in South African first-episode schizophrenia patients. (2014) (15)
P.2.c.025 Long-term treatment with agomelatine: prevention of relapse in patients with Major Depressive Disorder over 10 months (2008) (15)
How long should antipsychotic treatment be continued after a single episode of schizophrenia? (2016) (15)
Selective serotonin reuptake inhibitors in children and adolescents. (2002) (14)
Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia (2012) (14)
Land of promise: challenges and opportunities for research in South Africa (2004) (14)
Impaired water excretion and elevated plasma vasopressin in patients with alcohol-withdrawal symptoms. (1987) (14)
A brain-behaviour initiative for South Africa: the time is right (2006) (14)
Initiation Rites as a Perceived Stressor for Isixhosa Males with Schizophrenia (2007) (14)
HIV/AIDS risk behaviour in South African schizophrenia patients. (2007) (14)
Is the ongoing use of placebo in relapse-prevention clinical trials in schizophrenia justified? (2013) (14)
Suicide attempts in an African schizophrenia population: an assessment of demographic risk factors. (2004) (14)
Violence in Male Patients with Schizophrenia: Risk Markers in a South African Population (2004) (14)
Disordered Water Homeostasis in Schizophrenia and Cerebral Ventricular Size (1995) (14)
CAG repeat polymorphisms in KCNN3 (HSKCa3) and PPP2R2B show no association or linkage to schizophrenia (2003) (14)
Real-world data on paliperidone palmitate for the treatment of schizophrenia and other psychotic disorders: a systematic review of randomized and nonrandomized studies (2018) (13)
Nurses’ perceptions of medication adherence in schizophrenia: results of the ADHES cross-sectional questionnaire survey (2015) (13)
Community care of psychiatric disorders in South Africa--lessons from research on deinstitutionalization. (1999) (13)
Bilingualism and psychosis: A case report (2008) (13)
Bilingualism and psychosis: a linguistic analysis of a patient with differential symptom severity across languages (2009) (13)
Reward processing dysfunction in ventral striatum and orbitofrontal cortex in Parkinson's disease. (2017) (12)
HIV infection results in ventral–striatal reward system hypo-activation during cue processing (2015) (12)
Cognitive change after treatment for neurosyphilis. Correlation with CSF laboratory measures. (1995) (12)
Antipsychotic maintenance treatment in schizophrenia and the importance of preventing relapse (2018) (12)
Changes in brain regions associated with food-intake regulation, body mass and metabolic profiles during acute antipsychotic treatment in first-episode schizophrenia (2015) (12)
Brain ageing in schizophrenia: evidence from 26 international cohorts via the ENIGMA Schizophrenia consortium (2022) (12)
Forensic mental health services: Current service provision and planning for a prison mental health service in the Eastern Cape (2016) (11)
The Mental Health Information Centre of South Africa: a report of the first 500 calls. (1997) (11)
Cognitive changes in alcohol-induced psychotic disorder (2017) (11)
Thiazides, compulsive water drinking and hyponatraemic encephalopathy. (1984) (11)
Computed tomography in psychiatric patients. (1986) (11)
Fine-mapping of antipsychotic response genome-wide association studies reveals novel regulatory mechanisms. (2017) (11)
Resting brain perfusion in alcohol-induced psychotic disorder: A comparison in patients with alcohol dependence, schizophrenia and healthy controls (2010) (11)
Role of Newer Atypical Antipsychotics in the Management of Treatment-Resistant Schizophrenia (2000) (10)
Remission and employment status in schizophrenia and other psychoses: One-year prospective study in Croatian patients treated with risperidone long acting injection. (2016) (10)
Lessons from the past: Historical perspectives of mental health in the Eastern Cape (2014) (10)
10Kin1day: A Bottom-Up Neuroimaging Initiative (2019) (10)
Instruments Measuring Blunted Affect in Schizophrenia: A Systematic Review (2015) (10)
Psychiatric disorders and general medical conditions: implications for the clinician. (2008) (9)
Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia (2017) (9)
P.2.c.038 Long-term efficacy of agomelatine, a novel antidepressant, in the prevention of relapse in out-patients with major depressive disorder (2007) (9)
Introduction : The South African Society of Psychiatrists (SASOP) Treatment Guidelines for Psychiatric Disorders (2013) (8)
Psychiatry and technological advances: implications for developing countries (2000) (8)
Childhood trauma and hippocampal subfield volumes in first-episode schizophrenia and healthy controls (2020) (8)
Efficacy and tolerability of ‘Seroquel’ compared with haloperidol in schizophrenic patients partially responsive to conventional antipsychotic treatment (1999) (8)
Outcome of first-episode schizophrenia and the new antipsychotics. A literature review. (1996) (8)
Sub-specialties in psychiatry: towards parity in mental health training and services. (2009) (8)
The confirmatory factor structure of neurological soft signs in Nigerians with first episode schizophrenia (2015) (8)
The association between childhood trauma and treatment outcomes in schizophrenia spectrum disorders (2020) (8)
P.3.e.003 Predictors of abnormal involuntary movement in an African schizophrenia population (2007) (8)
Koro in Non-Chinese Subjects (1985) (8)
Vasopressin secretion and memory impairment in alcoholic Korsakoff's syndrome. (1995) (7)
Treatment of depressive symptoms in partially refractory schizophrenia: Efficacy of quetiapine versus haloperidol (2001) (7)
Non‐adherence and its consequences: understanding the nature of relapse (2013) (7)
Allocation of attention to the eye and mouth region of faces in schizophrenia patients (2008) (7)
Anxiety symptoms in schizophrenia: the need for heightened clinician awareness (2001) (7)
Psychiatric research in South Africa: a systematic review of Medline publications. (2001) (7)
Disability claims on psychiatric grounds. (1996) (7)
Endocrine function in alcoholic Korsakoff's syndrome. (1994) (7)
Cognitive-perceptual deficits and symptom correlates in first-episode schizophrenia (2017) (7)
Serotonergic agents in the treatment of hypothalamic obesity syndrome: a case report. (1996) (7)
New advances in pharmacotherapy for early psychosis (2009) (7)
Obesity and brain structure in schizophrenia – ENIGMA study in 3021 individuals (2022) (7)
Relationship between substance abuse and first-episode psychosis - a South African perspective (2003) (7)
Variation within voltage-gated calcium channel genes and antipsychotic treatment response in a South African first episode schizophrenia cohort (2018) (6)
Placebo controls in clinical trials: concerns about use in relapse prevention studies in schizophrenia (2016) (6)
A case of "ifufunyane": a xhosa culture-bound syndrome. (2005) (6)
Staff and bed distribution in public sector mental health services in the Eastern Cape Province, South Africa (2014) (6)
The prevalence of malingering in persons seeking compensation on the basis of neuropsychiatric symptoms (2001) (6)
First-episode psychosis: An update (2008) (6)
Psychiatric medications in primary care: algorithms and guidelines. (2000) (6)
Chromosome 22q11 in a Xhosa schizophrenia population. (2012) (5)
The usefulness of cerebrospinal fluid tests for neurosyphilis. (1994) (5)
Efficacy of Tianeptine 25-50 mg in Elderly Patients With Recurrent Major Depressive Disorder: An 8-Week Placebo- and Escitalopram-Controlled Study. (2018) (5)
Large-scale analysis of structural brain asymmetries in schizophrenia via the ENIGMA consortium (2022) (5)
Cost-effectiveness of an atypical conventional antipsychotic in South Africa: An economic evaluation of quetiapine versus haloperidol in the treatment of patients partially responsive to previous antipsychotics (2004) (5)
Prevalence and clinical correlates of police contact prior to a first diagnosis of schizophrenia (2017) (5)
Neurological Soft Signs, Spontaneous and Treatment Emergent Extrapyramidal Syndromes in Black Africans With First Episode Schizophrenia (2018) (5)
Relationship between changes in metabolic syndrome constituent components over 12 months of treatment and cognitive performance in first-episode schizophrenia (2019) (5)
Changing the course of schizophrenia - Predictors of treatment outcome revisited (2007) (5)
Neurosyphilis and Psychiatry (1988) (5)
Television as a medium for psycho-education in South Africa: analysis of calls to a mental health information centre after screening of a TV series on psychiatric disorders. (1999) (5)
Treatment challenges in schizophrenia (1999) (5)
Prevalence of obsessive compulsive disorder in first- and multi-episode male patients with schizophrenia-spectrum disorders. (2003) (5)
The quest for a meaningful evidence base in psychiatry (2009) (5)
ASENAPINE IN SCHIZOPHRENIA: AN OVERVIEW OF CLINICAL TRIALS IN THE OLYMPIA PROGRAM (2008) (5)
Self-induced water intoxication. A case report. (1988) (5)
On discontinuing treatment in schizophrenia: a clinical conundrum (2017) (4)
0395 REMISSION IN SCHIZOPHRENIA: RESULTS FROM A 12-MONTH ANALYSIS OF LONG-ACTING RISPERIDONE IN PATIENTS WITH FIRST-EPISODE PSYCHOSIS (2006) (4)
Magnetic Resonance Imaging in Alcoholic Korsakoff's Syndrome: Evidence for An Association with Alcoholic Dementia (1996) (4)
Discontinuing antipsychotic treatment after a first-episode of psychosis: Who, when and how? (2017) (4)
Safety and tolerability of lamotrigine in controlled mood disorder trials (2001) (4)
Health care discrimination against the mentally ill--a comparison of private health insurance benefits for major depressive disorder and ischaemic heart disease in South Africa. (2004) (4)
Season of birth, age and negative symptoms in a Xhosa schizophrenia sample from the Southern Hemisphere. (2006) (4)
P.3.a.012 A study of the clinical outcome following treatment discontinuation after remission in first-episode schizophrenia (2009) (4)
Amisulpride as adjunct to clozapine in treatment-resistant schizophrenia and schizoaffective disorder An open-label pilot study (2006) (4)
Validation of psychometric scales for malingering in a student sample (2001) (4)
Long-acting injectable antipsychotics in early psychosis (2011) (4)
Hippocampal subfield volumes and change in body mass over 12 months of treatment in first-episode schizophrenia spectrum disorders (2020) (3)
Anxiety and Schizophrenia (2007) (3)
Proposing the short Neurological Evaluation Scale (2016) (3)
Childhood trauma exposure and reward processing in healthy adults: A functional neuroimaging study (2022) (3)
The Potential Role of Regulatory Genes (DNMT3A, HDAC5, and HDAC9) in Antipsychotic Treatment Response in South African Schizophrenia Patients (2019) (3)
Explorer 10 Kin 1 day : A Bottom-Up Neuroimaging Initiative (2019) (3)
Exploratory factor structure of the neurological evaluation scale in black africans with first episode schizophrenia (2016) (3)
Season of Birth, Age and Negative Symptoms in a Xhosa Schizophrenia Sample from the Southern Hemisphere (2006) (3)
Indications for CAT scans of psychiatric patients. (1986) (3)
Early intervention in the management of schizophrenia: introduction (2009) (3)
Fronto-limbic white matter fractional anisotropy and body mass index in first-episode schizophrenia spectrum disorder patients compared to healthy controls (2020) (3)
Factors associated with placebo response in depression trials: A systematic review of published meta-analyses (1990–2017) (2018) (3)
Cannabis use and clinical outcome in people with first-episode schizophrenia spectrum disorders over 24 months of treatment (2021) (3)
Factors associated with poor satisfaction with treatment and trial discontinuation in chronic schizophrenia (2018) (3)
Gender role endorsement in first-episode schizophrenia spectrum disorders (2021) (3)
The expression of neurological soft signs in two African populations with first-episode schizophrenia (2018) (3)
Spontaneous and emergent extrapyramidal syndromes in Black Africans with first-episode schizophrenia and first exposure to antipsychotics (2020) (3)
Alcohol-induced psychotic disorder: brain perfusion and psychopathology—before and after anti-psychotic treatment (2011) (3)
Needs-based gap analysis for service transformation in the Eastern Cape (2015) (3)
Efficacy of seroquel in treating all of the positive and negative symptoms of schizophrenia (2000) (3)
RNA-seq analysis of gene expression profiles in posttraumatic stress disorder, Parkinson’s disease and schizophrenia identifies roles for common and distinct biological pathways (2022) (3)
35 – Long-term safety of asenapine in patients with schizophrenia (2008) (3)
The trajectories and correlates of two negative symptom subdomains in first-episode schizophrenia (2022) (2)
Sex versus gender as risk factors for the age of onset of schizophrenia spectrum disorders (2020) (2)
The one-month prevalence and correlates of psychotic-like experiences in the general adult population in Nigeria (2022) (2)
Cannabis use and hippocampal subfield volumes in males with a first episode of a schizophrenia spectrum disorder and healthy controls (2021) (2)
Cultural aspects of psychiatry (2000) (2)
Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes (2020) (2)
Low dose typical antipsychotics — a brief evaluation (2001) (2)
The course and concomitants of depression in first-episode schizophrenia spectrum disorders: A 24-month longitudinal study (2021) (2)
Early response to treatment predicts remission and recovery at 3 years in people with schizophrenia (2009) (2)
On discontinuing treatment in schizophrenia: a clinical conundrum (2017) (2)
Treatment with low-dose haloperidol does not protect against tardive dyskinesia (2003) (2)
Longer duration of breastfeeding associated with reduced risk of developing schizophrenia : article (2007) (2)
The multidimensional assessment of psychopathology in mood and psychotic disorders. A proposal for Axis II in DSM-V/ICD-11. (2008) (2)
Cognitive insight is associated with perceived body weight in overweight and obese adults (2021) (2)
0390 FIRST-LINE TREATMENT WITH LONG-ACTING RISPERIDONE IN PATIENTS WITH FIRST-EPISODE PSYCHOSIS:12 MONTHS SAFETY AND EFFICACY RESULTS (2006) (1)
The relationship between awareness of tardive dyskinesia and insight into mental illness in schizophrenia. (2009) (1)
Guest editorial: Special issue on maintenance treatment in schizophrenia (2020) (1)
Hair cortisol levels in schizophrenia and metabolic syndrome (2022) (1)
Management of violent behaviour in acutely relapsed schizophrenics. (2004) (1)
Prolactin, flupenthixol decanoate and first episode schizophrenia – clinical and laboratory correlates (2018) (1)
The new psychiatry. (1981) (1)
Correction to: Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations (2020) (1)
P-1241 - Nurses' Perceptions of Assessment, Causes and Management of Partial/non-adherence to Medication: Results of the Emea Adhes Survey in Schizophrenia (2012) (1)
The 3-year progression of clinically significant psychotic-like experiences in a general adult population in Lagos, Nigeria (2022) (1)
Poor insight increases relapse and re-admission to hospital in people with non-affective psychosis (2007) (1)
PW01-193 - Safety And Efficacy Of Long-Term Asenapine Versus Olanzapine In Schizophrenia Or Schizoaffective Disorder Patients (2010) (1)
A mental health information centre--integrating technology and community. (1996) (1)
Alcohol-induced psychotic disorder: a review (2013) (1)
S100. EFFECTS OF CANNABIS USE ON BODY MASS, FASTING GLUCOSE AND LIPIDS DURING THE FIRST 12 MONTHS OF TREATMENT IN SCHIZOPHRENIA SPECTRUM DISORDERS (2018) (1)
Sex and gender associations with indicators of neurodevelopmental compromise in schizophrenia spectrum disorders (2022) (1)
13th National Congress of the South African Society of Psychiatrists, 20-23 September 2004 (2004) (1)
The 2019 Schizophrenia International Research Society Conference, 10–14 April, Orlando, Florida: A summary of topics and trends (2019) (1)
Editorial: HIV/AIDS in Africa — a role for the mental health practioner? (2005) (1)
The associations of cannabis and methamphetamine use with cognitive performance over the first 2 years of treatment in schizophrenia spectrum disorders (2022) (1)
Re: Less is more (2014) (1)
Service transformation plans in the Eastern Cape informed by a needs-based gap analysis (2015) (1)
Antipsychotic treatment effects and structural MRI brain changes in schizophrenia (2021) (1)
A prospective study of clinical , biological and functional aspects of outcome in first episode psychosis (2015) (1)
The EMEA ADHES survey in schizophrenia: psychiatrists’ perceptions of the extent of assessment and management of partial and non-adherence to medication (2011) (1)
Associations of premorbid adjustment with type and timing of childhood trauma in first-episode schizophrenia spectrum disorders (2021) (1)
16th National Congress of the South African Society of Psychiatrists (SASOP) (2010) (1)
Differences in white matter microstructure in first-episode schizophrenia spectrum disorders vs healthy volunteers and their association with cognition (2022) (0)
Correction: Obesity and brain structure in schizophrenia – ENIGMA study in 3021 individuals (2022) (0)
The EMEA ADHES survey in schizophrenia: psychiatrists’ perceptions of reasons for partial or non- adherence (2011) (0)
Points: Radiology for psychiatric patients (1986) (0)
270 – Concordance of patient and clinical ratings regarding symptom severity and change (2008) (0)
The relationships between antipsychotic dose and efficacy, and the time to treatment response (2007) (0)
Poster #S108 INSTRUMENTS EVALUATING EMOTIONAL BLUNTING IN SCHIZOPHRENIA PATIENTS WITH NEGATIVE SYMPTOMS: A SYSTEMATIC REVIEW (2014) (0)
C.03.03 Optimisation of care in schizophrenia for relapse prevention with long-acting injectable antipsychotics (2017) (0)
Poster #T68 BRAIN SYSTEMS REGULATING FOOD-INTAKE AND BODY MASS CHANGES DURING ACUTE ANTIPSYCHOTIC TREATMENT IN FIRST-EPISODE SCHIZOPHRENIA (2014) (0)
A PROSPECTIVE STUDY OF THE CLINICAL OUTCOME FOLLOWING TREATMENT DISCONTINUATION AFTER 2 YEARS IN FIRST-EPISODE SCHIZOPHRENIA (2010) (0)
P0218 - Early cognitive response to treatment in first episode psychosis (2008) (0)
Poster #9 SOCIAL ISOLATION REARING IN RATS INDUCES SCHIZOPHRENIA-LIKE BEHAVIOURS THAT ARE REVERSED BY SUB-CHRONIC TREATMENT WITH CLOZAPINE OR N-ACETYL CYSTEINE (2012) (0)
The EMEA ADHES survey in schizophrenia, an initiative to raise awareness of non-adherence to medication. demographics and methodology (2011) (0)
384 – Bilingualism and psychosis: A case report (2008) (0)
Variation within voltage-gated calcium channel genes and antipsychotic treatment response in a South African first episode schizophrenia cohort (2018) (0)
Alcohol Induced Psychotic Disorder: a comparitive study in patients with alcohol dependance, schizophrenia and normal controls (2007) (0)
EARLY COGNITIVE RESPONSE TO TREATMENT IN FIRST EPISODE PSYCHOSIS (2008) (0)
Incidental neuroimaging findings in South African adult research participants with and without neuropsychiatric disorders (2022) (0)
C.09.01 How can we help our patients with schizophrenia adhere to their medication? (2011) (0)
S96. ASSOCIATIONS OF CHILDHOOD TRAUMA WITH HIPPOCAMPAL SUBFIELD VOLUMES IN FIRST-EPISODE SCHIZOPHRENIA PATIENTS AND HEALTHY CONTROLS (2019) (0)
C.12.01 The nature of relapse in schizophrenia (2014) (0)
Self-induced water intoxication (1988) (0)
Discontinuation of antipsychotics in remitted first episode psychosis; a survey of recent trials (2010) (0)
Psychosis and Antidiuretic Hormone (1984) (0)
FC07-05 - Resting brain perfusion in alcohol-induced psychotic disorder: A comparison in patients with alcohol dependence, schizophrenia and healthy controls (2011) (0)
C.06.01 The treatment continuum in schizophrenia from the acute phase to maintenance (2015) (0)
Corrigendum to “Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study” [Schizophrenia Research 93 (1–3) (2007) 117–130] (2007) (0)
Poster #193 BASELINE CHARACTERISTICS OF FIRST-EPISODE PSYCHOSIS PATIENTS IN CAPE TOWN (2012) (0)
Essential Fatty Acid Supplementation in Schizophrenia and Mood Disorders (2005) (0)
P.3.a.018 A role for structural equation modeling in subtyping schizophrenia in an African population (2010) (0)
Serum phosphate and anxiety in major depression (1990) (0)
Associations between BMI and brain structures involved in food intake regulation in first-episode schizophrenia spectrum disorders and healthy controls. (2022) (0)
Correction: Obesity and brain structure in schizophrenia - ENIGMA study in 3021 individuals. (2023) (0)
W67. PREDICTIVE UTILITY OF POLYGENIC RISK SCORES IN A SOUTH AFRICAN MIXED-ANCESTRY, PREVIOUSLY DRUG-NAïVE, FIRST-EPISODE SCHIZOPHRENIA COHORT (2021) (0)
Editorial (2009) (0)
Sleep quality and neurocognitive functioning in metabolic syndrome (2018) (0)
Selective serotonin reuptake inhibitorsin children and adolescents (2006) (0)
SCHIZOPHRENIAAND OBSESSIVE COMPULSIVE DISORDER - A LITERATURE REVIEW (1999) (0)
CAN THE ONGOING USE OF PLACEBO IN RELAPSE-PREVENTION CLINICAL TRIALS IN SCHIZOPHRENIA BE JUSTIFIED? (2014) (0)
Pharmacogenetics of Antipsychotic-Induced Weight Gain in Multiple Medication-Naive Cohorts (2017) (0)
Sexual dysfunction in first-episode schizophrenia spectrum disorders (2022) (0)
Inappropriate antidiuretic long-term psychiatric (1990) (0)
TU54. GENETIC VARIATION IN THE 5-HTTLPR AND REWARD PROCESSING: A NEUROIMAGING GENETICS STUDY (2021) (0)
S201. HIPPOCAMPAL SUBFIELD VOLUMES AND CHANGE IN BODY MASS OVER 12 MONTHS OF TREATMENT IN FIRST-EPISODE SCHIZOPHRENIA SPECTRUM DISORDERS (2020) (0)
C.01.02 New levels of outcome for first-episode patients treated with long-acting risperidone (2006) (0)
The causal role of accelerometer-derived sleep traits on glycated haemoglobin: a Mendelian randomization study (2022) (0)
The future of psychopharmacology: challenges beyond efficacy and tolerability (2023) (0)
A treatment algorithm for generalised anxiety disorder (2001) (0)
ffi cacy and Safety of Asenapine or Olanzapine in Patients with Schizophrenia or (2013) (0)
T86. RELEVANCE OF CANNABIS USE AS A PREDICTOR OF CLINICAL OUTCOME IN FIRST-EPISODE SCHIZOPHRENIA SPECTRUM DISORDER PATIENTS OVER 24 MONTHS OF TREATMENT (2020) (0)
Suicide attempts in an African schizophrenia population: An evaluation of risk factors and affected sibpair status (2003) (0)
S108. ASSOCIATIONS BETWEEN GLOBAL BRAIN MEASURES AND STATE- AND TRAIT- RELATED SYMPTOM EXPRESSION OF SCHIZOPHRENIA (2018) (0)
The EMEA ADHES survey in schizophrenia: psychiatrists’ perceptions of reasons for partial or non-adherence (2011) (0)
M102. MEASURING PHYSIOLOGICAL RESPONSES ASSOCIATED WITH SOCIAL STRESS IN A VIRTUAL ENVIRONMENT AND ITS RELATIONSHIP WITH CHILDHOOD TRAUMA IN EARLY SCHIZOPHRENIA - A PILOT STUDY (2020) (0)
"16th Association of European Psychiatrists Congress Nice, France05-09 April 2008Edited by Cyril Höschl and Philippe H. Robert (Emsley)" (2008) (0)
TIME COURSE OF EARLY TREATMENT RESPONSE AND ITS RELATIONSHIP TO REMISSION IN FIRST-EPISODE SCHIZOPHRENIA (2008) (0)
Co-occurrence of schizophrenia and obsessive compulsive disorder : a literature review (1999) (0)
Biological Psychiatry Congress 2015 (2015) (0)
T4. CHILDHOOD TRAUMA AND ITS RELATIONSHIP WITH PREMORBID ADJUSTMENT, COGNITION AND TREATMENT OUTCOMES IN FIRST EPISODE SCHIZOPHRENIA (2019) (0)
Studies in the psychopathology, neurobiology and psychopharmacology of schizophrenia (2008) (0)
The EMEA ADHES survey in schizophrenia, an initiative to raise awarenes (2011) (0)
309 – An open-label trial of risperidone long-acting injectable (2008) (0)
Arginine vasopressin hypersecretion and impaired water excretion in psychiatric disorders (1987) (0)
Erratum: Extrapyramidal side effects in first-episode schizophrenia treated with flupenthixol decanoate (2021) (0)
P.2.129 Risk for akathisia in patients with recent onset schizophrenia treated with risperidone and haloperidol and its association with suicidality (2003) (0)
The effects of HIV on the ventral-striatal reward system (2013) (0)
Extrapyramidal side effects in first-episode schizophrenia treated with flupenthixol decanoate (2021) (0)
Second-generation antipsychotics - a panacea? (2004) (0)
P.3.d.031 The appropriate pharmacological management of recent-onset schizophrenia: an international panel study using the RAND/UCLA methodology (2016) (0)
Reply to Letter to the Editor "Possible Dose-Response Relationship for Risperidone in Obsessive-Compulsive Disorder" (1998) (0)
CNS volume 24 issue 4 Cover and Front matter (2019) (0)
Clinical trials in psychiatry: Obtaining the evidence (2004) (0)
O3.2. CANNABIS USE AND HIPPOCAMPAL SUBFIELD VOLUMES IN MALES WITH FIRST-EPISODE SCHIZOPHRENIA AND HEALTHY CONTROLS (2019) (0)
Alcohol and brain damage. (1993) (0)
Schizophrenia and associated psychotic disorders (2000) (0)
Randomised Study of Ethyl-Eicosapentaenoic Acid versus Placebo as Supplemenal Treatment in Schizophrenia. (2003) (0)
021 WITHDRAWN (2016) (0)
F106. STATE AND TRAIT RELATED NATURE OF INSIGHT IMPAIRMENT IN SCHIZOPHRENIA (2018) (0)
M122. DEPRESSION IN SCHIZOPHRENIA SPECTRUM DISORDERS: LONGITUDINAL COURSE AND THE RELATIONSHIP WITH OTHER CLINICAL PARAMETERS AND QUALITY OF LIFE (2020) (0)
C.06.02 Early effective treatment in schizophrenia – what are the options? (2009) (0)
P3.e.024 Social cognition: response to treatment in first episode psychosis (2009) (0)
Relationship between changes in metabolic syndrome constituent components over 12 months of treatment and cognitive performance in first-episode schizophrenia (2019) (0)
Measuring the impact of HIV on the fronto-striatal system (2016) (0)
Physician awareness of partial and non-adherence to antipsychotic medication in schizophrenia: results from a survey conducted across Europe, the Middle East and Africa (2010) (0)
CT scanning in psychiatry. (1986) (0)
Factors associated with dropout at 2 years post-initiation of treatment in the first episode of schizophrenia (2021) (0)
P.3.a.017 Do attitudes towards medication adherence in schizophrenia vary between stakeholders? A comparison of survey results (2012) (0)
Medical research in South Africa--a psychiatric perspective. (1996) (0)
Poster #T45 CHANGES IN BODY MASS AND METABOLIC PROFILES OVER 12 MONTHS IN PATIENTS WITH FIRST-EPISODE SCHIZOPHRENIA WITH ASSURED ANTIPSYCHOTIC ADHERENCE (2014) (0)
P.3.d.089 Changes in body mass and metabolic profiles over 12 months in patients with first-episode schizophrenia treated with flupenthixol decanoate (2015) (0)
P.1.a.004 Chromosomal aberrations in an African schizophrenia population (2008) (0)
A retrospective review of the clinical and psychosocial profile of psychotic adolescents with comorbid substance use disorders presenting to acute psychiatric services at Tygerberg hospital (2012) (0)
BILINGUALISM AND PSYCHOSIS: A CASE REPORT (2008) (0)
The effects of HIV on the fronto-striatal system (2013) (0)
DEVELOPMENT AND IMPLEMENTATION IN GHANA , SOUTH AFRICA , UGANDA AND ZAMBIA (2008) (0)
Establishing a neuropsychiatry clinic at Tygerberg hospital (1999) (0)
IMPACT OF METHAMPHETAMINE USE IN FIRST EPISODE PSYCHOSIS (2010) (0)
Liver enzymes in patients with schizophrenia (2005) (0)
Positive and Negative Symptoms in Xhosa Sibling Pairs With Schizophrenia (2005) (0)
P.3.e.003 Predictors of abnormal involuntary movement in an African schizophrenia population (2008) (0)
T2. ADVERSE CHILDHOOD EXPERIENCES IN PEOPLE WITH SCHIZOPHRENIA (2020) (0)
"AN OPEN-LABEL TRIAL OF RISPERIDONELONG-ACTING INJECTABLE" (2008) (0)
ASSESSING THE IMPACT OF POSSIBLE COVERT POOR COMPLIANCE IN EARLY PSYCHOSIS: A CROSS-STUDY COMPARISON OF ORAL VS. INJECTABLE ANTIPSYCHOTIC TREATMENT (2008) (0)
First-episode psychosis: lessons from 15 years of research (2001) (0)
The 15th Biannual National Congress of the South African Society of Psychiatrists, 10-14 August 2008, Fancourt, George, W Cape (2008) (0)
SU92 MODIFICATION OF THE ASSOCIATION BETWEEN MMP9 GENE VARIANTS AND ANTIPSYCHOTIC TREATMENT RESPONSE BY CHILDHOOD ADVERSITY IN A FIRST-EPISODE SCHIZOPHRENIA COHORT (2019) (0)
The relationship between neurocognitive functioning and metabolic syndrome (MetS) parameters and the interaction effect of cognitive insight in non-psychiatric individuals (2017) (0)
Cognitive changes in alcohol-induced psychotic disorder (2017) (0)
41.3 ASSOCIATIONS BETWEEN CHILDHOOD TRAUMA AND PREMORBID ADJUSTMENT, COGNITIVE PERFORMANCE AND BRAIN STRUCTURE AND CONNECTIVITY IN SCHIZOPHRENIA AND HEALTHY CONTROLS (2019) (0)
P.2.b.008 Effect of agomelatine and escitalopram on emotional experiences in outpatients suffering from major depressive disorder (2017) (0)
Targets for treating the full spectrum of symptoms of schizophrenia (2009) (0)
AGREEMENT OF PATIENT AND CLINICAL RATINGS REGARDING SYMPTOM SEVERITY OF PSYCHOTIC ILLNESS (2008) (0)
A role for structural equation modelling in subtyping schizophrenia in an African population (2010) (0)
Poster #186 THE EMEA ADHES SURVEY IN SCHIZOPHRENIA: NURSES’ VIEWS ON THE TREATMENT OPTIONS FOR IMPROVING PARTIAL OR NON-ADHERENCE IN PATIENTS WITH SCHIZOPHRENIA (2012) (0)
Amisulprideof its Use in the Management of Schizophrenia (2001) (0)
RELAPSE – RISK AND PREVENTION (2014) (0)
Effects of acute antipsychotic treatment on brain morphology in schizophrenia (2013) (0)
Social cognition: response to treatment in first episode psychosis (2009) (0)
Poster #185 THE EMEA ADHES SURVEY IN SCHIZOPHRENIA: NURSES’ PERCEPTIONS OF THE EXTENT AND BURDEN OF PARTIAL AND NON-ADHERENCE TO MEDICATION IN PATIENTS WITH SCHIZOPHRENIA (2012) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Robin Alexander Emsley?

Robin Alexander Emsley is affiliated with the following schools:

Stellenbosch University